Avid Bioservices Inc (CDMO)

[biopharm]

3) PPHM may close deals with friendly parties (with on the shelf shares - as I posted in the past having a strong shelf is GOOD for contingency and protection against a HOSTILE ATTACK from RONIN is certainly a contingency worthy situation). Those share in the hands of a BP would melt down ALL OTHER VOTING power.

Nice post and again, worthwhile to read it all several times....yet I am only taking this portion out of your post because now, I believe 100% how important it was to get this shelf approved last year and I am very hopeful there will be some parties as close allies to Peregrine looking to increase positions (Ken Dart..) and others looking to guarantee their alliances to Peregrine ...

If Ronin tries to dare go to court to speed up ASM which I doubt they can be allowed to....but maybe some will still stop at nothing to stop PS Targeting

PS: How can patents be filed by Ivana Turbachova and Sven Olek (Epiontis) after the passing of Ivana ? Maybe North may know but maybe this patent was based upon earlier patents when Ivana Turbachova was alive ....so patents based upon an earlier filed one, can maintain the names ....

This buyout by Precision For Medicine of Epiontis (both were working and collaborating with Peregrine prior) and I don't know if this buyout helps Peregrine or hinders anything, which is why I started months ago with reasoning that any new patents based upon new knowledge via PS Targeting should have rights back to Peregrine ...

Maybe, if this does hinder Peregrine in some way, it can be questioned why Bird & Bird had facts that supported advising Precision For Medicine to buy out Epiontis...and it certainly couldn't have been advised to buy them out due to them working with Peregrine Pharmaceuticals (as this has to be based upon BIOMARKERS data concluded by way of collaborations with Peregrine ..)

Epigenetic Markers for the Identification of Blood Sub-cells of Type 1
Publication number: 20170233807
Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or naïve T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof.
Type: Application
Filed: April 3, 2017
Publication date: August 17, 2017
Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased

https://patents.justia.com/inventor/ivana-t-rbachova